Practical considerations on the restoration of sexual function in the hypogonadal man

Alvaro Morales MD FRCSC

Insidious hypogonadism that is associated with aging has most of the same manifestations as andropause, but its development is subtle. A response to treatment is usually prompt in hypogonadal men experiencing sexual dysfunction. It is recommended that patients with hypogonadism and sexual dysfunction receive treatment for three months. In the absence of a response at that time, comorbidities should be sought out actively. The results of treatment are not spectacular. This observation reflects the fact that, in aging men, hormonal shifts are only one of many other comorbid conditions (eg, atherosclerosis, peripheral neuropathy, emotional disturbances).

Key Words: Androgens; Intramuscular injections; Oral route; Percutaneous gel; Transdermal patch

ANDROGEN DEFICIENCY IN THE AGING MALE AND SEX: CLINICAL PICTURE

In contrast to menopause, the process of androgen deficiency in the aging male or andropause, but its development is subtle. A response to treatment is usually prompt in hypogonadal men experiencing sexual dysfunction. It is recommended that patients with hypogonadism and sexual dysfunction receive treatment for three months. In the absence of a response at that time, comorbidities should be sought out actively. The results of treatment are not spectacular. This observation reflects the fact that, in aging men, hormonal shifts are only one of many other comorbid conditions (eg, atherosclerosis, peripheral neuropathy, emotional disturbances).

Key Words: Androgens; Intramuscular injections; Oral route; Percutaneous gel; Transdermal patch

Observations pratiques relatives au rétablissement du fonctionnement sexuel chez les hommes atteints d'hypogonadisme

RÉSUMÉ : L’hypogonadisme insidieux associé au vieillissement présente à peu près les mêmes caractéristiques que l’andropause, mais celui-ci s’installe plus subtilement. La réaction au traitement est généralement rapide chez les hommes hypogonadiques présentant un dysfonctionnement sexuel. Il est recommandé de soumettre les hommes souffrant à la fois d’hypogonadisme et de dysfonctionnement sexuel à un traitement hormonal pendant trois mois. En l’absence de réaction, il faudrait chercher d’autres maladies concomitantes. Par ailleurs, les résultats du traitement ne sont pas spectaculaires. La remarque met en évidence le fait que le changement hormonal chez les hommes vieillissants ne constitue qu’une manifestation parmi d’autres, par exemple l’athérosclérose, la neuropathie périphérique, les troubles émotifs.
The andropause syndrome is characterized by the prominent and easily recognizable features of diminished sexual desire and erectile quality, particularly nocturnal erections; changes in mood, with concomitant decreases in intellectual activity and spatial orientation, fatigue, depression and anger; decreased lean body mass, with associated diminution in muscle volume and strength; decreased body hair and skin alterations; decreased bone mineral density, resulting in osteoporosis; and increased visceral fat. These manifestations need not all be present to diagnose the syndrome. In addition, the severity of one or more of the above symptoms does not necessarily match the severity of the other symptoms, and the uneven presence of these manifestations is not yet understood. Sexual dysfunction, however, is recognized as one of the most constant features of andropause.

THERAPEUTIC OPTIONS

Therapy of hypogonadism is generally medical, as opposed to surgical (pituitary tumours), and effective. For the clinician, the goals of treatment most commonly include the restoration of sexual functioning, libido and a sense of well-being. As indicated in previous papers in the present issue, it is equally important that androgen replacement can prevent or improve already established osteoporosis, optimize bone density, restore muscle strength, improve mental acuity and normalize growth hormone levels, especially in elderly men. Testosterone replacement therapy should maintain not only physiological levels of serum testosterone, but also the metabolites of testosterone, including dihydrotestosterone (DHT) and estradiol (E2) to optimize the maintenance of libido, virilization and sexual function. It is worth noting that in the Massachusetts Male Aging Study, the only sex hormone correlating with sexual dysfunction was dehydroepiandrosterone. This sole correlation, of course, points to the shortcomings of epidemiological data and transdermal patches (scrotal and nonscrotal). Neither injectable preparations nor slow release pellets reproduce the circadian pattern of testosterone production of the testes. The latter is best accomplished by dermal patches; however, oral testosterone may also approximate a circadian rhythm by dose adjustments. Common testosterone preparations are shown in Table 1.

Oral preparation

Oral preparations of testosterone require special consideration. Oral agents that are available include alkylated androgen preparations (to prevent rapid hepatic metabolism), which generally result in erratic androgenic effects and significant changes in lipid profile, and have a high risk of adverse liver side effects (2). The hepatotoxicity causes hepato-cellular adenoma, cholestatic jaundice and hemorrhagic liver cysts (3). In addition, alkylated androgens may result in increased low density lipoprotein and decreased high density lipoprotein levels, with the resultant potential for increased cardiovascular risks (4). Testosterone undecanoate is widely used throughout the world (with the notable exception of the United States). As a testosterone ester, it is free of liver toxicity and effective in bringing levels of serum testosterone to within physiological range. It may, however, result in supraphysiological levels of DHT and rare gynecomastia (5). The drug is lipid soluble and should be taken with meals. The recommended dose is 120 to 200 mg in three divided doses, depending on the degree of testosterone deficiency, body surface, obesity and clinical response.

IM injections

IM injections of testosterone are usually long-acting. These formulations obtain a maximum concentration approximately 72 h after injection, which slowly diminishes over the ensuing 10 to 14 days. The gradual decline frequently results in a very low nadir before injection is repeated (6). Parenteral androgens do not provide normal circadian patterns of serum testosterone, and the injections are somewhat uncomfortable. Levels of DHT are normal, but androgen

### Table 1

<table>
<thead>
<tr>
<th>Available formulations in Canada</th>
<th>Generic name</th>
<th>Trade name</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injectable</td>
<td>Testosterone cypionate</td>
<td>Depo-Testosterone Cypionate (Pharmacia &amp; Upjohn Inc, Canada)</td>
<td>200 to 400 mg every 3 to 4 weeks</td>
</tr>
<tr>
<td></td>
<td>Testosterone enanthate</td>
<td>Delatestryl (Theramed Corporation, Canada)</td>
<td>200 to 400 mg every 4 weeks</td>
</tr>
<tr>
<td>Oral</td>
<td>Fluoxymesterone*</td>
<td>Halotestin (Pharmacia &amp; Upjohn Inc)</td>
<td>5 to 20 mg/day</td>
</tr>
<tr>
<td></td>
<td>Methyltestosterone*</td>
<td>Metandren (Novartis, Canada)</td>
<td>10 to 30 mg/day</td>
</tr>
<tr>
<td></td>
<td>Testosterone undecanoate</td>
<td>Andriol (Organon Canada Inc, Canada)</td>
<td>120 to 160 mg/day</td>
</tr>
<tr>
<td>Transdermal</td>
<td>Testosterone patch</td>
<td>Androderm (SmithKline Beecham, Canada)</td>
<td>6 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Testoderm (Alza Canada, Canada)</td>
<td>10 to 15 mg/day</td>
</tr>
<tr>
<td></td>
<td>Testosterone gel</td>
<td>Androgel (Solvay Pharma Inc, Canada)</td>
<td>2.5 to 5 g./day</td>
</tr>
</tbody>
</table>

*Just as with 17-alpha alkylated testosterone products, both fluoxymesterone and methyltestosterone are associated with serious liver toxicity*
Androderm (Smithkline Beecham, Canada) and Testoderm are now available for nonscrotal use, and include the nadir seen before patch replacement. Transdermal patches testosterone levels achieved in the early morning and testosterone secretion. Patches are applied at bedtime, with peak variations of testosterone observed in normal human testosterone that is absorbed transdermally to obtain normal serum testosterone levels. These preparations use elemental testosterone recently became available worldwide (8). Transdermal more physiological approach to testosterone replacement, testosterone therapy is essential.

In patients undergoing parenteral testosterone injections are anecdotal. Careful counselling about the possibility of these mood and behavioral changes for patients undergoing parenteral testosterone therapy is essential.

Transdermal testosterone therapy, a more expensive but more physiological approach to testosterone replacement, recently became available worldwide (8). Transdermal testosterone therapy is available in both scrotal and nonscrotal patches. These preparations use elemental testosterone that is absorbed transdermally to obtain normal serum testosterone levels and reproduce the diurnal physiological variations of testosterone observed in normal human testosterone secretion. Patches are applied at bedtime, with peak testosterone levels achieved in the early morning and a nadir seen before patch replacement. Transdermal patches are now available for nonscrotal use, and include the Androderm (Smithkline Beecham, Canada) and Testoderm (Alza Canada, Canada) systems (9,10). These nonscrotal patches also maintain diurnal serum concentrations, with normal E2 and DHT levels. While most patients can be treated with a single nonscrotal transdermal patch, patients need varying amounts of testosterone replacement, depending on the patients’ deficiency and absorption characteristics. Morning testosterone levels should be evaluated within two to three weeks of initiating therapy to identify peak testosterone levels. Serum evaluations of these patients should be carried out between 08:00 and 10:00 to determine the highest daily level of serum testosterone produced by the patch. Because androgen levels with these systems do not increase beyond normal, it is unlikely that detrimental changes in mood occur with transdermal preparations. While psychological effects have not been carefully studied in a long term series, no cases of aggressiveness with the transdermal patch systems have been reported (11). Follow-up studies of transdermal testosterone replacement have, however, showed an improvement in testosterone levels associated with improved sexual function, libido and nocturnal penile tumescence response, with the maintenance of normal hematocrit levels, lipid profile, prostate-specific androgen (PSA) levels and prostatic volumes (12). The most common negative effects associated with the dermal patches include the inconvenience of applying them and dermatitis, which sometimes leads to significant chemical burns (13).

A transdermal testosterone hydroalcoholical gel preparation (Androgel, Solvay Pharma Inc, Canada ) is a new addition to the armamentarium. When applied to skin, it dries up in less than 5 min, and early reports indicate that it is well tolerated (insignificant skin irritation) and can be applied to the same site without increasing dermatological problems or decreasing efficacy. Regarding efficacy, administration of the testosterone gel results in the normalization of the serum values of testosterone. The levels of DHT tend to be above normal. The experience with this delivery form is short, and there is a lack of dose-ranging studies (14). Nevertheless, short term studies (six months) indicate that this preparation results in improved sexual function and mood, and increased lean body mass and muscle strength that are associated with a decrease in fat mass (15). These studies are the most compelling to date, but are very limited in sample size and the length of follow-up.

RESULTS OF TREATMENT

The benefit of dealing with hypogonadal men experiencing sexual dysfunction is that a response to treatment is usually prompt. It is recommended that patients with hypogonadism and sexual dysfunction receive treatment for three months. In the absence of a response at that point, comorbidities should be sought out actively. The results of treatment are not spectacular. This observation reflects the fact that, in aging men, hormonal shifts are only one of many other conditions (eg, atherosclerosis, peripheral neuropathy, emotional disturbances) that affect these patients.
REFERENCES